New and future immunomodulatory therapy in type 1 diabetes

详细信息	查看全文 | 推荐本文 |

• 作者：James E. Tooley ; Frank Waldron-Lynch ; Kevan C. Herold ^{kevan.herold@yale.edu}
• 关键词：type 1 diabetes ; immunotherapy ; metabolic therapy ; biologics
• 刊名：Trends in Molecular Medicine
• 出版年：2012
• 期刊代码：259_14714914
• 类别：med
• 出版时间：March, 2012
• 卷：18
• 期：3
• 页码：173-181
• 文件大小：478 K

摘要

Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting 尾 cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.